Ph1 CPX-351 combined with various agents in previously untreated AML - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how safe and effective it is for patients with newly diagnosed AML to take the study drug, CPX-351 given in combination with venetoclax, midostaurin or enasidenib.

What is the Condition Being Studied?

Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Who Can Participate in the Study?

Adults with newly diagnosed AML who:
- Do not have acute promyelocytic leukemia
- Have not received prior treatment intended for induction therapy of AML
- Are not receiving any therapy for MDS

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Take the study drug (CPX-351) by infusion (into the vein) at the clinic
-Have blood drawn
-Have a physical exam
-You will participate in the study anywhere from 42-224 days, depending on how much you need

Study Details

Full Title
V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Subjects with Previously Untreated Acute Myeloid Leukemia
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00104012
NCT: NCT04075747
Phase
Phase I/II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698